These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 1322029

  • 1. Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Khan S, Mehta JL.
    Am Heart J; 1992 Aug; 124(2):280-8. PubMed ID: 1322029
    [Abstract] [Full Text] [Related]

  • 2. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ.
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [Abstract] [Full Text] [Related]

  • 3. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 4. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 5. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
    Nichols WW, Nicolini FA, Khan S, Saldeen TG, Mehta JL.
    Am Heart J; 1993 Aug; 126(2):285-92. PubMed ID: 7687816
    [Abstract] [Full Text] [Related]

  • 6. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 7. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U, Fischer S, Sponer G.
    J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
    [Abstract] [Full Text] [Related]

  • 8. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D.
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
    Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Laywell E, Kitzen J, Lucchesi BR.
    Circulation; 1990 Feb; 81(2):617-27. PubMed ID: 2105175
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ.
    Pharmacology; 1991 Dec; 42(6):340-8. PubMed ID: 1946598
    [Abstract] [Full Text] [Related]

  • 16. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS, Zoldhelyi P, Webster MW, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH.
    Circulation; 1996 Feb 15; 93(4):792-9. PubMed ID: 8641009
    [Abstract] [Full Text] [Related]

  • 17. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
    Yasuda T, Gold HK, Fallon JT, Leinbach RC, Garabedian HD, Guerrero JL, Collen D.
    J Am Coll Cardiol; 1989 May 15; 13(6):1409-14. PubMed ID: 2495318
    [Abstract] [Full Text] [Related]

  • 18. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
    Mehta JL, Chen L, Nichols WW, Johannesen M, Bregengård C, Hedner U, Saldeen TG.
    J Am Coll Cardiol; 1995 Mar 01; 25(3):753-60. PubMed ID: 7860925
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
    Nicolini FA, Mehta JL, Nichols WW, Saldeen TG, Grant M.
    Circulation; 1990 Mar 01; 81(3):1115-22. PubMed ID: 1689620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.